INTRODUCTION
Oral controlled release drug delivery systems offer a number of advantages over the conventional immediate release delivery preparations. These systems are designed to deliver the drugs at a controlled and predetermined rate thus maintaining their therapeutically effective concentration in systemic circulation for prolonged period. On the other hand, for certain therapies a pulsatile drug release pattern, where the drug is released after welldefined lag time, exhibits significant advantages. It is well documented that most of the body functions display circadian rhythms, e.g. heart rate, stroke volume, blood pressure, blood flow, body temperature, gastric-pH. 1 Moreover, in a number of organs their functions vary with the time of the day. It is increasingly recognized that there are rhythmic and temporal patterns in the manifestation of many disease states. The symptoms for a number of diseases, such as bronchial asthma, myocardial infarction, angina pectoris, hypertension, rheumatic diseases etc. follow a circadian rhythm. 2 Circadian rhythms are self-sustaining, endogenous oscillations that occur with a periodicity of about 24 Hours. 3 Interestingly, the term circadian is derived from the Latin circa which means "about" and dies which can be defined as "a day". Normally, circadian rhythms are synchronized according to internal biologic clocks related to the sleep-wake cycle. Our circadian rhythm is based on sleep-activity cycle and is influenced by our genetic makeup and thereby affects our body's function throughout day and night (24-hour period). Circadian rhythm regulates many body functions in humans like metabolism, physiology, behaviour, sleep pattern, hormone production 4 as many conditions show circadian pattern, advantage could be taken by timing and adjusting the administration of drugs according to the circadian rhythm of the disease.
Oral pulsatile administration could be useful for the treatment of certain diseases, such as asthma, gastric ulcer, hypertension, ischemic heart disease, arthritis, etc., which exhibit circadian rhythms. A pulsatile release profile is characterized by a lag time followed by rapid and complete drug release. Most pulsatile systems are reservoir systems and usually covered with a barrier. This barrier can be dissolved, eroded or removed at a predetermined period of time after which the drug is dissolved and rapidly released.
Meloxicam is an nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Prostaglandins are substances that contribute to inflammation of joints. Meloxicam inhibits prostaglandin synthetase (cylooxygenase 1 and 2) and leads to a decrease of the synthesis of prostaglandins, therefore, inflammation is reduced.
5 Pulsatile drug delivery system is a controlled drug delivery system where drug is released after a preprogrammed lag time. Various approaches have been used to design a pulsatile release formulation, erodible devices provided with hydrophilic polymer coating are widely used and such a system when exposed to dissolution medium undergo swelling, dissolution and/or erosion. Lag time in such a system can be controlled by using various hydrophilic polymers such as HPMC, polyethylene oxide, sodium alginate, sodium CMC. The concentration and viscosity of these polymers play a significant role in controlling the lag time and release pattern. 6 A Capsular system in which the body part coated with impermeable polymer and hydrophilic matrix plug sealing the drug formulation is used to prepare pulsatile drug delivery system. Upon contact with aqueous fluids a rapid dissolution would occur and plug undergoes a gradual swelling and finally expluded from the body thus allowing the drug to release. The lag time in such formulation controlled by the time needed for the plug removal and its duration depends on the physical, chemical nature, size and position of the plug.
The aim of the present work is to develop a simple one pulse drug delivery system based on dry coated tablet preparation. The system consist of a core tablet containing the drug, an impermeable outer shell and top cover layer barrier that dissolves at predetermined time. Ethyl cellulose is used as insoluble material and a Polyethylene oxide 301, Polyethylene oxide 303 and Hydroxy propyl cellulose used as hydrophilic top layer. The drug is released after removal of top layer of hydrophilic polymers and the lag time being adjusted by properties of the material in top cover, Meloxicam is used as model drug.
MATERIALS AND METHOD

Materials:
Meloxicam were obtained from Jai Radhe Sales Ahmedabad, India. Ethyl cellulose, L-Hydroxy propyl cellulose, Polyethylene oxides were gifted from Colorcon Asia Pvt.Ltd. Micro Crystalline Cellulose Croscarmellose Sodium, Magnesium Stearate, Potassium Dihydrogn Phosphate, Disodium Hydrogen Phosphate was obtained from Loba Cheim Pvt. Ltd. All the other chemicals and reagents were either analytical or pharmaceutical grades.
Tablet Manufacturing Method
Formulation of Core Tablet by Direct Compression Method:
The rapid release core tablets were prepared using a compression machines (Labpress) with suitable flat punches. The core was made of the suitable mixture of powder blends of Meloxicam, Microcrystalline Cellulose (MCC, Avicel PH-102), Croscarmellose Sodium (Ac-DiSol), Sodium starch glycolate and Magnesium stearate was used in different batches. All above ingredients were dry blended for 20 minutes followed by addition of Magnesium Stearate. The mixture was then further blended for 10 minutes. The 80 mg of the resultant mixture then directly compressed at a pressure of 1 ton for 1minute using 6 mm punch and die. Shown in Table no.1 Table No1 :-Composition of Core Tablet
Formulation of Press Coated Tablet by Direct Mixing:
In this method the coating material mixtures were previously passed through the sieve no. 44 and half quantity of the powder mixture was used for the upper and lower shell. The press coating of tablets was performed using a rotary tablet machine. A half amount of the powder was filled into the die to make a powder bed, in the center of which core tablet was placed manually. Then, the remaining half of the coating material filled in the die, and the contents were compressed under a sufficient compression force, using a suitable punch. Shown in Table  no. 2   Table 2 
: Composition of Press Coated Tablet by Direct Mixing
Formulation of Press Coated Tablets by Impermeable Cup Shaped Method:
An impermeable coating cup consisting of ethyl cellulose was applied in the bottom and around the core tablet. The ethyl cellulose powder was filled into a die of 10mm diameter and then was gently compacted to make a powder bed with a flat surface. The core tablet was in turn carefully placed in centre of powder bed next the die was filled with the reminder of the coating powder so that -150  150  FA2  80  200  100  --150  150  FA3  80  225  75  --150  150  FA4  80  250  50  --150  150  FB1  80  250  -50  -150  150  FB2  80  260  -40  -150  150  FB3  80  270  -30  -150  150  FB4  80  280  -20  -150  150  FC1  80  250  --50  150  150  FC2  80  260  --40  150  150  FC3  80  270  --30  150  150  FC4  80  280  --20  150 surrounding surfaces of the core tablet was fully covered. On the top hydrophilic polymer was added and last bed was compressed to produce the desired core-in-cup system. Shown in Evaluation of core and press -coated tablet Preformulation Study:
Bulk density, tapped density, hausner's ratio, carr's index and angle of repose was perform for polymeric blends.
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Characterization of Core and Press Coated Tablets
Thickness:
Thickness of tablets was determined using Vernier caliper. Five tablets from batch were used, and average values were calculated.
Average Weight:
To determine average weight, each tablet from formulation was weighed using an electronic balance.
Hardness:
The hardness was tested using Monsanto tester. The force is measured in kilograms/cm 2 .
Uniformity of Content:
The tablet from each batch was powdered individually and a quantity equivalent to 80mg of Meloxicam was accurately weighed and dissolved in a suitable volume of 6.8 pH phosphate buffer. After making suitable dilutions the final solution was analyzed spectrophotometrically at λmax of drug.
Friability:
For each formulation, the friability of 6 tablets was determined using the Roche friabilator (Lab Hosp.).
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Twenty tablets were initially weighed (Initial Wt) and transferred into friabilator. The Friabilator was operated at 25 rpm for 4 minutes or run up to 100 revolutions. The tablets were weighed again (Final Wt). The % friability was then calculated by,
Disintegration Test:
Six core tablets were selected randomly from each batch for the disintegration test. Disintegration test was performed in simulated colonic fluid (SCF) using Veego Disintegration Tester (microprocessor based), and Disintegration time (DT) was measured.
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Drug Excipient Interaction:
Compatibility of the Drug with the excipients is determined by subjecting the physical mixture of the drug and the polymers of the main formulation to infrared absorption spectral analysis (FTIR). Any changes in chemical composition of the drug after combining it with the polymers were investigated with I.R. spectral analysis.
In vitro Drug Release Study of Press Coated Tablets:
Dissolution studies were carried out using USP Apparatus II (Veego) at a rotation speed of 50 rpm and at 37 ± 0.5°C using 900 mL of 0.1 N HCl for two hours, followed by 900 mL of pH 6.8 phosphate buffer as the dissolution media. At appropriate time intervals, 1ml dissolution samples were withdrawn and replaced with 1ml of fresh solution maintained at the same temperature. Samples were analyzed by ultraviolet visible spectrophotometry (Shimadzu UV-1800, Japan). The amount of Meloxicam dissolved in the dissolution media was then determined from the calibration curve and the cumulative percentage of Meloxicam released was calculated.
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Stability Study:
After determining the drug content, the optimized batches of tablet were monitored up to 1 month at accelerated stability conditions of temperature and relative humidity (40° ± 2°C /75%± 5%RH). Samples were withdrawn after one month and characterized for Appearance, Weight, Thickness, Hardness, drug content, drug release. The choice of appropriate storage condition during accelerated stability study is necessary to predict the long term stability of Meloxicam tablet. The humidity during storage is also extremely important, considering the hygroscopic nature of hydrophilic polymers .12 The powder blend indicated good flowability with the angle of repose values ranging from 26° to 36° according to fixed funnel method. The results of bulk density, tapped density and compressibility index are shown in Table No. 4. The result of compressibility index was between 16.12±1.36 to 20.78±2.13, which indicates good to fair flow properties. Post compression characterization of core tablet are performed and all result are found to be within pharmacopeial limit which is shown in Table No . 5 The core tablets were found to have disintegration time in following order A1 < A2 < A3 < A4 < A5 Thus, it was found that formulation A5 shows least disintegration time of about 76 seconds. Tablets A5 It contains Cross Carmellose Sodium in concentration of 8 % hence it was selected for further study. All data related to disintegration are shown Figure 
In Vitro Drug Release Study of Core Tablets:
The core tablet formulation (A5) containing highest amount of Cross Carmellose Sodium showed fast disintegration. Shown in Figure No It was found that direct mixing methods may permeate dissolution media from all sides of tablets because of presence of hydrophilic polymer it diffuses drug from all sides but in impermeable cup shaped method dissolution media do not enter from all sides because presence of hydrophobic polymer it can enter into only one side that is top layer which is hydrophilic. This gets eroded slowly and exposes tablet. Hence in impermeable method thickness of top layer is directly proportional to lag time of tablet. Shown in Figure The stability study of the FF4 batch in which the tablets were monitored. There was little bit but no large difference was observed in the evaluation of the FF4 batch. The dissolution study of the optimized batch at zero month and one month show no changes in drug release profile both the dissolution study show the typical pulsatile profile. All data of Stability study Shown in Table No Figure 13: % drug release before and after stability Study
CONCLUSION
Results of present work demonstrated that combination of both hydrophilic and hydrophobic polymers by impermeable cup shaped method could be successfully employed for formulating pulsatile release tablets of Meloxicam. The FF4 formulation combination of Ethyl Cellulose (bottom cup) and Polyox 303 (top layer) was capable of extending the drug release after 6 hours.
